A biomarker analysis showed a better PFS for patients with low-tumor PDGFR-alpha RNA in the combination arm, suggesting the relevance of tumor vascular microenvironment when combining angiogenesis and EGFR inhibitors. The gene discussed is EGFR; the disease is neoplasm.